Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
519 studies found for:    "chronic graft versus host disease"
Show Display Options
Rank Status Study
1 Terminated Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD)
Condition: Chronic Graft Versus Host Disease
Intervention: Other: PET-CT Scan
2 Recruiting Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)
Conditions: Chronic Graft-Versus-Host Disease;   Acute Graft-Versus-Host Disease;   Steroid Refractory Graft-Versus-Host Disease
Interventions: Drug: Rapamycin;   Other: T regulatory cells
3 Recruiting Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
Condition: Chronic GVHD
Interventions: Drug: Sirolimus + calcineurin inhibitor + prednisone;   Drug: Sirolimus + prednisone
4 Unknown  Study of Rituximab in Patients With Steroid-Refractory Chronic Graft-Versus-Host Disease
Condition: Steroid-Refractory Chronic GVHD
Intervention: Drug: Rituximab
5 Active, not recruiting Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)
Condition: Chronic Graft-versus-host Disease
Intervention: Drug: Rituximab
6 Recruiting Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease
Conditions: Chronic Graft Versus Host Disease;   Chronic GVHD;   Complications of Organ Transplant Stem Cells
Interventions: Other: Treg-enriched infusion;   Drug: Interleukin-2
7 Terminated
Has Results
Alefacept in Subjects With Steroid-Refractory Chronic Graft-versus-Host Disease
Condition: Chronic Graft-versus-host Disease
Intervention: Drug: Alefacept
8 Recruiting Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease
Condition: Chronic Graft Versus Host Disease
Intervention: Drug: Ofatumumab
9 Completed Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children
Condition: Graft vs Host Disease
Intervention: Drug: Pentostatin
10 Recruiting Mesenchymal Stem Cells for Treatment of Refractory Chronic Graft-versus-host Disease
Condition: Chronic Graft-versus-host Disease
Interventions: Biological: Mesenchymal stem cells;   Biological: Non-mesenchymal stem cells
11 Recruiting Treatment of Chronic Graft-Versus-Host Disease With Mesenchymal Stromal Cells
Condition: Chronic Graft-Versus-Host Disease
Intervention: Biological: Mesenchymal Stromal Cells
12 Withdrawn A Study of Panobinostat (LBH589) as Second-Line Therapy in Patients With Chronic Graft-Versus-Host Disease
Condition: Chronic Graft-Versus-Host Disease
Interventions: Drug: LBH589;   Drug: Methylprednisolone
13 Withdrawn Pentostatin, Cyclophosphamide Plus Rituximab (PCR) for the Therapy of Poor-Prognosis Chronic Graft-Versus-Host Disease
Condition: Active Chronic Graft Versus Host Disease
Intervention: Drug: Pentostatin; Cyclophosphamide; Rituximab
14 Active, not recruiting A Safety and Efficacy Study of Uvadex and Extracorporeal Photopheresis (ECP) in Chronic Graft Versus Host Disease
Condition: Chronic Graft Versus Host Disease
Interventions: Drug: ECP(Methoxsalen)+Corticosteroids+Cyclosporine or Tacrolimus;   Drug: Corticosteroids/Cyclosporine/Tacrolimus
15 Unknown  Treatment of Chronic GVHD of Liver or Lungs by ECP
Condition: Chronic Graft-Versus Host Disease
Intervention: Procedure: Extracorporeal photoimmunotherapy
16 Active, not recruiting Improving Outcomes Assessment in Chronic GVHD
Condition: Chronic Graft Versus Host Disease
Intervention:
17 Unknown  Prospective Phase II Study for Assessment of Regulatory Immune Cell Populations After Allogeneic HSCT
Condition: Allogeneic Hematopoietic Cell Transplant Recipients
Intervention:
18 Unknown  Efficacy and Safety Study of Allogenic Mesenchymal Stem Cells for Patients With Chronic Graft Versus Host Disease
Condition: Chronic Graft Versus Host Disease
Interventions: Biological: Biological: mesenchymal stem cell;   Drug: Cyclosporine and Glucocorticoid
19 Unknown  Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease
Condition: Graft vs Host Disease
Intervention: Drug: Alemtuzumab and Rituximab combination
20 Recruiting An Open Label Phase II Trial of Topical Sirolimus for the Treatment of Refractory Oral Chronic Graft-versus-Host-Disease
Conditions: Chronic Graft-versus-Host-Disease;   Oral Mucosal Disease Due to Graft-versus-host Disease
Intervention: Drug: Sirolimus

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years